Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) Director Chris Anigeron Rallis sold 1,186 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of C$9.68, for a total value of C$11,485.70.
Fennec Pharmaceuticals Stock Performance
TSE FRX opened at C$9.80 on Friday. The stock’s fifty day moving average is C$8.91 and its two-hundred day moving average is C$7.73. The firm has a market capitalization of C$188.99 million, a P/E ratio of -166.01 and a beta of 0.25. The company has a debt-to-equity ratio of -620.83, a quick ratio of 10.17 and a current ratio of 7.80. Fennec Pharmaceuticals Inc. has a fifty-two week low of C$5.65 and a fifty-two week high of C$15.20.
Analyst Upgrades and Downgrades
Separately, Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Further Reading
- Five stocks we like better than Fennec Pharmaceuticals
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- P/E Ratio Calculation: How to Assess Stocks
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- How to Most Effectively Use the MarketBeat Earnings Screener
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
